2021
Targeting STAT3 prevents bile reflux‐induced oncogenic molecular events linked to hypopharyngeal carcinogenesis
Vageli DP, Doukas PG, Siametis A, Judson BL. Targeting STAT3 prevents bile reflux‐induced oncogenic molecular events linked to hypopharyngeal carcinogenesis. Journal Of Cellular And Molecular Medicine 2021, 26: 75-87. PMID: 34850540, PMCID: PMC8742186, DOI: 10.1111/jcmm.17011.Peer-Reviewed Original ResearchConceptsBcl-2 overexpressionTranscriptional activationTranscription factorsTranscriptional activitySignal transducerSTAT3 knockdownMolecular eventsCell survivalQPCR analysisLuciferase assaySTAT3 activationTargeting STAT3Oncogenic eventsAberrant activationHypopharyngeal carcinogenesisSTAT3 phosphorylationSTAT3Oncogenic effectsSTAT3 pathwayPharmacologic inhibitionPharmacological inhibitionSTA-21Hypopharyngeal cellsOncogenic profileWestern blot
2020
The in vivo preventive and therapeutic properties of curcumin in bile reflux‐related oncogenesis of the hypopharynx
Doukas SG, Doukas PG, Sasaki CT, Vageli D. The in vivo preventive and therapeutic properties of curcumin in bile reflux‐related oncogenesis of the hypopharynx. Journal Of Cellular And Molecular Medicine 2020, 24: 10311-10321. PMID: 32691972, PMCID: PMC7521262, DOI: 10.1111/jcmm.15640.Peer-Reviewed Original ResearchConceptsNF-κBRecent pre-clinical studiesHuman hypopharyngeal cellsIndependent risk factorPre-clinical studiesNF-κB activationTherapeutic propertiesHypopharyngeal cellsRisk factorsMolecular eventsHypopharyngeal mucosaBile exposureImmunohistochemical analysisFuture translational developmentBile acidsOncogenic profileHypopharynxCarcinogenic effectsOncogenic functionOverexpression of RelAEpithelial cellsBileTranslational developmentExpression of genesCurcumin
2019
Temporal characteristics of NF-κB inhibition in blocking bile-induced oncogenic molecular events in hypopharyngeal cells
Doukas PG, Vageli DP, Doukas SG, Sasaki CT. Temporal characteristics of NF-κB inhibition in blocking bile-induced oncogenic molecular events in hypopharyngeal cells. Oncotarget 2019, 10: 3339-3351. PMID: 31164956, PMCID: PMC6534360, DOI: 10.18632/oncotarget.26917.Peer-Reviewed Original ResearchAcidic bileNF-κB inhibitorBAY 11Hypopharyngeal cellsIL-6MiR-155MiR-375Specific NF-κB inhibitorMiR-21NF-κB inhibitionPre-neoplastic eventsEsophageal refluxLaryngopharyngeal cancerRisk factorsMolecular eventsEarly neoplasiaTherapeutic implicationsMiR-192MiR-451aClinical useWestern blotB activationBileOncogenic factorB inhibitor